Holen Sie sich die Stockscreener-App
0.3919
8.84%
-0.038
Schlusskurs vom Vortag:
$0.4299
Offen:
$0.4168
24-Stunden-Volumen:
5.51M
Relative Volume:
0.90
Marktkapitalisierung:
$145.66M
Einnahmen:
$52.29M
Nettoeinkommen (Verlust:
$-134.84M
KGV:
-0.5225
EPS:
-0.75
Netto-Cashflow:
$-117.11M
1W Leistung:
-17.06%
1M Leistung:
+0.49%
6M Leistung:
-26.61%
1J Leistung:
-57.43%
1-Tages-Spanne:
$0.38
$0.4222
1-Wochen-Bereich:
$0.38
$0.55
52-Wochen-Spanne:
$0.345
$1.06
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Firmenname
Sangamo Therapeutics Inc
Sektor
Branche
Telefon
(510) 970-6000
Adresse
501 CANAL BLVD., RICHMOND, CA
Compare SGMO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.3919 | 159.79M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-12-13 | Hochstufung | Truist | Hold → Buy |
| 2024-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-01-07 | Fortgesetzt | Guggenheim | Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-12-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-09-08 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | SunTrust | Buy |
| 2019-08-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-10-10 | Eingeleitet | Guggenheim | Buy |
| 2018-06-20 | Eingeleitet | BofA/Merrill | Buy |
| 2017-11-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2016-11-01 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-10-19 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-10-23 | Fortgesetzt | Jefferies | Buy |
| 2013-05-03 | Eingeleitet | BioLogic Equity Research | Sell |
| 2011-02-23 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-07-29 | Bestätigt | Wedbush | Outperform |
| 2009-10-19 | Eingeleitet | Brean Murray | Sell |
| 2009-10-07 | Bestätigt | Leerink Swann | Outperform |
| 2009-08-25 | Bestätigt | JMP Securities | Mkt Outperform |
Alle ansehen
Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten
Risk Report: Does Sangamo Therapeutics Inc have consistent dividend growth - baoquankhu1.vn
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update - MarketBeat
Merger Talk: Does Sangamo Therapeutics Inc have consistent dividend growth2025 Buyback Activity & Technical Pattern Based Buy Signals - baoquankhu1.vn
SGMO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sangamo (NASDAQ: SGMO) CEO surrenders shares for RSU tax withholding - Stock Titan
Sangamo (NASDAQ: SGMO) SVP surrenders shares to cover RSU tax withholding - Stock Titan
EDGAR Filing Documents for 0001628280-24-042308 - SEC.gov
symbol__ Stock Quote Price and Forecast - CNN
SGMO Should I Buy - Intellectia AI
Retail Trends: Is Sangamo Therapeutics Inc a strong growth stock2025 Volatility Report & Capital Protection Trading Alerts - baoquankhu1.vn
Sangamo Therapeutics (SGMO) price target increased by 17.31% to 3.89 - MSN
How liquid is Sangamo Therapeutics Inc. stockExit Point & Smart Investment Allocation Tips - mfd.ru
Is Sangamo Therapeutics Inc. stock a hidden gem2025 Trading Recap & Consistent Profit Focused Trading Strategies - mfd.ru
Is Sangamo Therapeutics Inc. benefiting from innovation trendsWeekly Investment Report & Expert Verified Movement Alerts - mfd.ru
FY2030 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat
Sangamo Therapeutics' (SGMO) Buy Rating Reiterated at HC Wainwright - MarketBeat
SGMO: HC Wainwright & Co. Maintains Buy Rating with $10 PT | SGM - GuruFocus
Assessing Sangamo Therapeutics (SGMO) Valuation After New Fabry Data Financing Move And Leadership Changes - simplywall.st
Sangamo starts FDA submission seeking approval of Fabry gene therapy - Fabry Disease News
Sangamo prices $25 million offering of common stock and warrants By Investing.com - Investing.com Nigeria
What Sangamo Therapeutics (SGMO)'s Fabry Gene Therapy Progress And Equity Raise Means For Shareholders - Sahm
Sangamo Biosciences launches dilutive February 2026 financing - TipRanks
Sangamo Therapeutics Signs Multiple Material Agreements - TradingView
Form 424B5 SANGAMO THERAPEUTICS, - StreetInsider
Sangamo To Present Positive Study Data Of ST-920 In Fabry Disease At WORLD Symposium 2026 - Nasdaq
Should FDA Accelerated Approval Pathway for ST-920 Gene Therapy Data Require Action From Sangamo Therapeutics (SGMO) Investors? - Yahoo Finance
Sangamo (SGMO) Appoints Interim CFO Amid Leadership Change - GuruFocus
Sangamo Therapeutics (SGMO) Price Target Increased by 17.31% to 3.89 - Nasdaq
Sangamo gene therapy shows positive kidney function results in Fabry disease - Investing.com India
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 - The Manila Times
Sangamo gene therapy shows positive kidney function results in Fabry disease By Investing.com - Investing.com South Africa
One-time Fabry gene therapy lifts kidney function in early trial data - Stock Titan
Sangamo Shares Fall After Pricing $25 Million Public Offering - marketscreener.com
Sangamo Therapeutics (SGMO) Stock Plummets 28% After $25M Offeri - GuruFocus
Sangamo stock plunges after pricing $25 million dilutive offering By Investing.com - Investing.com India
Sangamo Prices $250 Mln Offering; Stock Plunges - Nasdaq
Sangamo stock plunges after pricing $25 million dilutive offering - Investing.com
Sangamo plunges after pricing stock offering; principal financial officer exits - Seeking Alpha
Sangamo Therapeutics reports preliminary cash balance and CFO transition By Investing.com - Investing.com Australia
Sangamo Therapeutics reports preliminary cash balance and CFO transition - Investing.com Nigeria
Sangamo Therapeutics to Raise $25 Million Through Public Offering of Common Stock - geneonline.com
Sangamo Therapeutics IncOn Feb 2, Prathyusha Duraibabu terminated as principal financial officerSEC filing - marketscreener.com
Sangamo (SGMO) Appoints Nikunj Jain as Interim CFO - GuruFocus
Sangamo (SGMO) Announces New Stock Offering to Raise $25M - GuruFocus
Sangamo (SGMO) Reports Estimated Year-End Cash Holdings - GuruFocus
Sangamo Therapeutics slides after $25 million stock sale - TradingView
Sangamo Therapeutics Prices Underwritten Offering of Common Stock and Warrants, Expected to Raise Approximately $25 Million - Quiver Quantitative
Sangamo prices $25 million offering of common stock and warrants - Investing.com
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering - The Manila Times
Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Stock's 29% Jump Looks Justified - 富途牛牛
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Boosted 29% But Its Business Prospects Need A Lift Too - simplywall.st
Finanzdaten der Sangamo Therapeutics Inc-Aktie (SGMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.71%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):